Aspen has reported an annual revenue increase of 9 per cent to R38.6 billion boosted by growth from Commercial Pharmaceuticals and 22 per cent increase from its Manufacturing sector. The group has not declared an annual dividend amid the volatile market conditions, but it continues to ramp up production of its COVID-19 treatment drug dexamethasone. Aspen CEO, Stephen Saad joins CNBC Africa for more.
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.